Uterine leiomyosarcoma: 14-year two-center experience of 31 cases.
OBJECTIVE
The aim of this study was to evaluate the clinicopathological characteristics of uterine leiomyosarcoma (LMS) and possible prognostic factors.


METHODS
This study included 31 patients with histologically proven LMS at Samsung Medical Center and Ajou University Hospital between 1994 and 2007. The medical records and available histological slides were reviewed retrospectively.


RESULTS
The median age was 46 years (range, 32~63). The most common symptom was vaginal bleeding (11 patients, 35.5%). There were 23 patients with stage I, one patient with stage III, seven patients with stage IV disease. The median follow up time was 29 months (range, 1~94). The most common recurrence site was lung (5 case), followed by pelvis and upper abdomen (2 case). Nine patients died of disease with a 5-year overall survival rate of 63%. Early tumor stage and mitotic count were the prognostic factor in univariate analysis (p<0.0001 and p=0.0031, respectively), but early tumor stage only was associated with prognosis in multivariate analysis (p=0.010 vs p=0.143). Adjuvant treatment for early stage disease did not decrease the recurrence rate (p=0.1075), but high mitotic count (15>10HPF) had a trend for disease recurrence in early stage LMS (p=0.0859).


CONCLUSIONS
Mitotic count less than 15/HPF in early stage may be related with longer progression-free interval, but we could not reach the conclusion that adjuvant therapy in early stage LMS be effective.
Kim
Woo Young
WY
Department of Obstetrics and Gynecology, Ajou University Hospital, Suwon, Korea.
Chang
Suk-Joon
SJ
Chang
Ki-Hong
KH
Yoon
Jong-Hyuck
JH
Kim
Jang Hee
JH
Kim
Byoung-Gie
BG
Bae
Duk-Soo
DS
Ryu
Hee-Sug
HS
Obstet Gynecol. 1988 Jun;71(6 Pt 1):845-50
2453004
Gynecol Oncol. 1999 Aug;74(2):196-201
10419731
Tumori. 1983 Feb 28;69(1):75-7
6836752
Am J Obstet Gynecol. 1990 Apr;162(4):968-74; discussion 974-6
2327466
Cancer. 1986 Apr 15;57(8):1451-4
3948125
Cancer. 1978 Sep;42(3):1152-60
698910
Acta Oncol. 1990;29(2):185-91
2334571
Hum Pathol. 1970 Sep;1(3):331-49
4330001
Cancer. 1998 Nov 1;83(9):1972-9
9806656
Gynecol Oncol. 1996 Jul;62(1):25-32
8690287
Gynecol Oncol. 2003 Jun;89(3):460-9
12798712
Gynecol Oncol. 1996 Aug;62(2):226-9
8751554
Gynecol Oncol. 1998 Jan;68(1):54-61
9454661
Curr Opin Oncol. 2004 Jul;16(4):324-7
15187886
Gynecol Oncol. 2007 Jul;106(1):82-8
17434579
Gynecol Oncol. 2006 Jan;100(1):166-72
16182349
Gynecol Oncol. 1985 Mar;20(3):354-63
2982707
Cancer. 1996 Dec 15;78(12):2543-50
8952563
Gynecol Oncol. 1993 Jul;50(1):105-9
8349151
Cancer. 1993 Feb 15;71(4 Suppl):1702-9
8381710
Gynecol Oncol. 1984 Oct;19(2):168-72
6489828
Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1366-73
14630275
Cancer. 1990 Jul 1;66(1):35-9
2354406